Fluticasone/salmeterol, sold under the brand name Advair among others, is a combination medication containing fluticasone propionate and salmeterol. It is used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is used by breathing the medication into the lungs.
Fluticasone propionate (top)
and salmeterol (bottom)
|Salmeterol||Long-acting β2 agonist (LABA)|
|Trade names||Advair, Seretide, others|
|AHFS/Drugs.com||FDA Professional Drug Information|
Common side effects include thrush, headache, and cough. Serious side effects may include worsening asthma, anaphylaxis, seizures, and heart problems. Safety in pregnancy and breastfeeding is unclear. Fluticasone, a steroid, works by decreasing inflammation while salmeterol, a LABA, works by activating beta-2 adrenergic receptors.
The combination was approved for medical use in the United States in 2000. A generic version was approved in the United States in 2019. A two month supply in the United Kingdom costs the NHS about 35.00 £ per month as of 2019. In the United States the wholesale cost of this amount is about 89.00 USD. In 2016, it was the 62nd most prescribed medication in the United States, with more than 12 million prescriptions.
Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination which decreases inflammation in the lungs. This leads to better breathing. Salmeterol, a long acting beta-adrenoceptor agonist (LABA), treats constriction of the airways. The combination of both is meant to be used as maintenance therapy and not as a rescue therapy for sudden symptoms.
The common and minor side effects of this combination are those of its individual drugs. For instance, the use of inhaled corticosteroids is associated with oral candidiasis, commonly known as yeast infection or thrush. It is recommended to rinse and gargle with water after inhaling the medication. This decreases the risk of developing a Candida infection.
While the use of inhaled steroids and long acting beta-adrenoceptor agonists (LABA) are recommended in asthma guidelines for the resulting improved symptom control, concerns have been raised that salmeterol may increase the small risks of asthma deaths and this additional risk is not reduced with the additional use of inhaled steroids. Other side effects from this drug combination may include increased blood pressure, change in heart rate, an irregular heartbeat, increased risk of osteoporosis, cataracts, and glaucoma. With available studies, the safety of inhaled fluticasone propionate cannot be questioned for its effect on growth of asthmatic children. A systematic review published in 2013 could not derive any significant adverse effect on the function of the hypothalamic–pituitary–adrenal axis, growth, and bone mineral density in asthmatic children when inhaled fluticasone is used for a long duration and followed for up to three months.
Society and cultureEdit
In 2012, Advair was part of a larger civil settlement agreement between GlaxoSmithKline (GSK) and the United States, in which GSK agreed to pay $1.043 billion; the United States said that GSK promoted off-label uses of Advair and paid kickbacks to healthcare professionals to sell this drug, among others.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 263–264. ISBN 9780857113382.
- "Fluticasone and Salmeterol inhalation - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 4 March 2019.
- "Fluticasone / salmeterol Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- Office of the Commissioner. "Press Announcements - FDA approves first generic Advair Diskus". www.fda.gov. Retrieved 1 February 2019.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
- "Guideline 101: British Guideline on the Management of Asthma". British Thoracic Society & Scottish Intercollegiate Guidelines Network (SIGN).
- Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE (June 2006). "Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths". Ann. Intern. Med. 144 (12): 904–12. doi:10.7326/0003-4819-144-12-200606200-00126. PMID 16754916.
- "US fluticasone propionate/Salmeterol label" (PDF). FDA. April 2016.
- Muley, Prasad; Shah, Monali (2013). "Safety of Inhaled Fluticasone Propionate Therapy for Pediatric Asthma - A Systematic Review". Current Drug Safety. 8 (3): 186-194. PMID 23859431.
- "FDA approves first generic Advair Diskus". U.S. Food and Drug Administration.
- "GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data". Department of Justice: Office of Public Affairs. July 2, 2012.